Loading...
Regulatory aspects of the development of drugs for metabolic bone diseases – FDA and EMA perspective
Regulation of medicines involves complex scientific and public health policies which are reflected in the regulatory approaches used by the European Medicines Agency and the United States Food and Drug Administration for the approval of products developed for metabolic bone diseases. For osteoporosi...
Na minha lista:
| Udgivet i: | Br J Clin Pharmacol |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley and Sons Inc.
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6533422/ https://ncbi.nlm.nih.gov/pubmed/30335197 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13791 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|